Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Samsung Biologics signs CDMO deal with US-based drugmaker
By Shim Woo-hyunPublished : Oct. 8, 2021 - 16:16
Samsung Biologics said Thursday that it had signed a contract development and manufacturing organization deal with Texas-based drugmaker Enzolytics.
The company did not disclose the financial terms.
Under the deal, Samsung Biologics will provide end-to-end CDMO services to help Enzolytics develop and manufacture investigational new drug treatments for HIV and COVID-19.
Samsung Biologics said it would provide a stable cell line from its research and development facility in San Francisco, while producing clinical trial materials for Enzolytics’ treatments at its facility in Incheon.
Samsung Biologics added that the two companies had agreed to discuss future deals for monoclonal antibodies that are currently under development by Enzolytics.
